IndiaEarly data from a clinical trial conducted by Insilico Medicine suggests that an AI-generated drug, rentosertib, may not only treat chronic lung disease but also potentially slow the aging process. The drug's molecular structure was developed using artificial intelligence, and results indicate it reduces biological markers of age according to six 'aging clocks', AI tools used to predict morbidity and mortality. This development highlights the growing role of AI in drug discovery and longevity research. However, the drug is still years away from regulatory approval, and its effects on healthy individuals remain untested. Experts acknowledge the promising findings but emphasize the need for further trials before making definitive conclusions.
Bias read (Center): The article discusses scientific advancements in AI-driven drug discovery and aging research without taking a political stance or showing bias toward any ideological perspective. It presents findings objectively, citing expert opinions and noting both potential benefits and limitations of the study.
